公司資料
Cellectar Biosciences 股價、新聞與催化劑
- 股票代碼:
- CLRB
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
2.56 USD (-1.54%)
收盤價
最後更新: 2026年8月17日
21.9M USD
市值
股價為何變動
As of Aug 17, 2026, CLRB closed down 1.54% at $2.56. No new same-company headline was identified in the current news window.
公司概覽
Phospholipid Drug Conjugate Platform
Cellectar Biosciences develops cancer therapies using its Phospholipid Drug Conjugate platform, which is designed to deliver radioisotopes selectively to malignant cells while limiting off-target exposure.
Iopofosine I 131
Iopofosine I 131 is the company’s lead radioconjugate and has produced clinical evidence in relapsed or refractory Waldenström macroglobulinemia. It has also been studied in multiple myeloma and central nervous system lymphoma.
CLR 125 Solid-Tumor Program
CLR 125 carries the Auger-emitting isotope iodine-125 and is being evaluated initially in triple-negative breast cancer, with potential application in lung and colorectal cancers.
Regulatory Strategy
Cellectar plans a confirmatory study of iopofosine in Waldenström macroglobulinemia to support a potential FDA filing under the Accelerated Approval pathway.
未來催化劑
- Initiation of enrollment in the confirmatory Phase 3 iopofosine I 131 study in Waldenström macroglobulinemia.
- NDA submission for iopofosine I 131 under the accelerated-approval pathway in mid-2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。